Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL
US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL
US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL
Submitted by
admin
on November 8, 2014 - 11:39am
Source:
PharmaBiz
News Tags:
diffuse large B-cell lymphoma
lymphoma
MorphoSys
MOR208
Headline:
US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL
Do Not Allow Advertisers to Use My Personal information
